

RÉSUMÉ DIGEST

ACT 374 (SB 253)

2026 Regular Session

McMath

New law provides that no professional or occupational licensing board shall prohibit a healthcare provider with prescriptive authority from providing patients with peptides shipped from either of the following:

- (1) A FDA-registered 503B outsourcing facility that is in compliance with 21 U.S.C. 353b.
- (2) A 503A compounding pharmacy that is in compliance with 21 U.S.C. 353a and applicable United States Pharmacopeia - National Formulary chapters.

New law provides that no professional or occupational licensing board shall prohibit a La. licensed pharmacist in a state permitted pharmacy from compounding and dispensing peptides as long as the pharmacist and pharmacy are in compliance with 21 U.S.C. 353a and applicable United States Pharmacopeia - National Formulary chapters.

Effective August 1, 2026.

(Adds R.S. 37:23.5)